What neuroscience drugs does Otsuka sell?
Otsuka Pharmaceutical maintains a robust global neuroscience product portfolio that includes several cornerstone medications prescribed for psychiatric and neurological conditions. Their flagship neuroscience lineup features products such as Abilify (aripiprazole) and extended-release versions like Abilify Maintena and Abilify Asimtufii, Rexulti (brexpiprazole) for major depressive disorder and schizophrenia, and Nuedexta for pseudobulbar affect. These medications provide essential symptom management for patients dealing with chronic mental health disorders worldwide.
Related FAQs
Otsuka is a significant multi-industry conglomerate, and its market capitalization, which serves as the most accurate measure of its public worth, stands at approximately ₹608.22 billion as of July 2026 [1.5.1].
Otsuka Holdings Co., Ltd. functions as a publicly traded corporate entity rather than a privately held enterprise.
The share price of Otsuka Holdings Co., Ltd. (traded on the Tokyo Stock Exchange under the ticker 4578) is approximately 11,500.00 JPY.
Otsuka Holdings Co., Ltd. trades on the Tokyo Stock Exchange under the primary stock code 4578.
Otsuka Pharmaceutical is a research-driven healthcare enterprise that develops and manufactures a wide-ranging portfolio of pharmaceutical drugs, prescription medications, and specialized nutritional products.